DAROLUTAMIDE

Details

Stereochemistry	EPIMERIC
Molecular Formula	C19H19ClN6O2
Molecular Weight	398.846
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](CN1C=CC(=N1)C2=CC(Cl)=C(C=C2)C#N)NC(=O)C3=NNC(=C3)C(C)O

InChI

InChIKey=BLIJXOOIHRSQRB-PXYINDEMSA-N

InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H19ClN6O2
Molecular Weight	398.846
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	1 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://newdrugapprovals.org/2016/03/12/odm-201/
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26137992 | https://www.ncbi.nlm.nih.gov/pubmed/26313416

ODM-201 (also known as BAY-1841788) is a non-steroidal antiandrogen, specifically, a full and high-affinity antagonist of the androgen receptor (AR), that is under development by Orion and Bayer HealthCare for the treatment of advanced, castration-resistant prostate cancer (CRPC). ODM-201 appears to negligibly cross the blood-brain-barrier. This is beneficial due to the reduced risk of seizures and other central side effects from off-target GABAA receptor inhibition that tends to occur in non-steroidal antiandrogens that are structurally similar to enzalutamide. Moreover, in accordance with its lack of central penetration, ODM-201 does not seem to increase testosterone levels in mice or humans, unlike other non-steroidal antiandrogens. Another advantage is that ODM-201 has been found to block the activity of all tested/well-known mutant ARs in prostate cancer, including the recently-identified clinically-relevant F876L mutation. ODM-201 has been studied in phase I and phase II clinical trials and has thus far been found to be effective and well-tolerated, with the most commonly reported side effects including fatigue, nausea, and diarrhea. No seizures have been observed.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 169 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992	Antagonist 2849		65.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Prostate cancer 186 Sources: https://clinicaltrials.gov/ct2/show/NCT02799602	Primary		Phase III 665	Unknown Approved Use Unknown
Non-metastatic castration-resistant prostate cancer 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02200614	Primary		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
4.79 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ODM-201 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
52.82 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ODM-201 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
20 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ODM-201 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	Disc. AE: Cardiac failure, Hypertension... AEs leading to discontinuation/dose reduction: Cardiac failure (0.4%) Hypertension (0.6%) Diarrhea (0.5%) Pneumonia (0.5%) Fatigue (0.7%) Hypertension (0.3%) Nausea (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
900 mg 2 times / day steady, oral Highest studied dose Dose: 900 mg, 2 times / day Route: oral Route: steady Dose: 900 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/24974051	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/24974051	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf https://pubmed.ncbi.nlm.nih.gov/24974051

AEs

AE	Significance	Dose	Population
Hypertension	0.3% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
Nausea	0.3% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
Cardiac failure	0.4% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
Diarrhea	0.5% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
Pneumonia	0.5% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
Hypertension	0.6% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
Fatigue	0.7% Disc. AE	600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	unhealthy, 74 years (range: 48–95 years) Health Status: unhealthy Age Group: 74 years (range: 48–95 years) Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 P-gp 1741 BCRP 910 OATP1B1 1079 OATP1B3 961 OAT1 725 OAT3 747 OCT1 620 OCT2 779 BSEP 550 MRP2 499 MATE1 415 MATE2 267 NTCP 39	UGT1A9 423 UGT1A1 479 UGT1A8 323 UGT2B17 237 UGT1A3 470 P-gp 2052 BCRP 697

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 4.46 uM]		unlikely (co-administration study) Comment: no change in the total and renal clearance of rosuvastatin by darolutamide Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0
MRP2 625	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >10 uM]	KETO-DAROLUTAMIDE 1
NTCP 40	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >10 uM]	KETO-DAROLUTAMIDE 1
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >10 uM]	KETO-DAROLUTAMIDE 1
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >2 uM]	KETO-DAROLUTAMIDE 1
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >2 uM]	KETO-DAROLUTAMIDE 1
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >2 uM]	KETO-DAROLUTAMIDE 1
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >300 uM]	KETO-DAROLUTAMIDE 1
MRP2 625	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >50 uM]
NTCP 40	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >50 uM]
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >50 uM]
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >50 uM]
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >50 uM]
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	no [IC50 >60 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf#page=7 Page: 7.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	weak		weak (co-administration study) Comment: decreased the mean exposure (AUC) and Cmax of midazolam by 29% and 32%, respectively; did not show any increase but a mean decrease of less than 20% in the mean exposure (AUC) and Cmax of non-conjugated or total dabigatran Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 0.567 uM]	KETO-DAROLUTAMIDE 1
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 1.33 uM]		yes (co-administration study) Comment: showed a 5.2-fold increase in AUC and a 4.9-fold increase in Cmax of rosuvastatin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 16.4 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 16.8 uM]		unlikely (co-administration study) Comment: no change in the total and renal clearance of rosuvastatin by darolutamide Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 2.57 uM]	KETO-DAROLUTAMIDE 1
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 2.96 uM]	KETO-DAROLUTAMIDE 1
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 32.3 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 39.3 uM]		unlikely (co-administration study) Comment: no change in the total and renal clearance of rosuvastatin by darolutamide Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 9.5 uM]
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 >10 uM]	KETO-DAROLUTAMIDE 1
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 >10 uM]	KETO-DAROLUTAMIDE 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	yes [IC50 >10 uM]	KETO-DAROLUTAMIDE 1

Drug as victim

Target	Modality	Activity	Clinical evidence
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	yes
UGT1A1 479	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	yes
UGT1A3 470	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	yes
UGT1A8 323	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	yes
UGT1A9 423	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	yes
UGT2B17 237	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 71.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 72.0	yes	yes (co-administration study) Comment: significant reduction in darolutamide exposure (72% reduction in darolutamide AUC72) when it is concomitantly used with rifampin; Inhibition of CYP3A4 and P-gp by itraconazole increased darolutamide exposure (AUC72) by 1.7 fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 72.0
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 72.0	yes	yes (co-administration study) Comment: significant reduction in darolutamide exposure (72% reduction in darolutamide AUC72) when it is concomitantly used with rifampin; Inhibition of CYP3A4 and P-gp by itraconazole increased darolutamide exposure (AUC72) by 1.7 fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=71 Page: 72.0

Tox targets

Target	Modality	Metabolite
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	(S,R)-darolutamide 1
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	(S,S)-darolutamide 1
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf#page=72 Page: 72.0	KETO-DAROLUTAMIDE 1

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA000TJW	https://www.aablocks.com/goods/Goods/detail?id=AA000TJW
Aaron Chemicals	AR000UBO	http://www.aaronchem.com/1297538-32-9
abcr GmbH	AB479454	http://www.abcr.com/shop/en/AB479454
AbMole Bioscience	M9956	http://www.abmole.com/products/darolutamide.html
Achemtek	0102-028666	http://www.achemtek.com/1297538-32-9
Ambeed	A147162	https://www.ambeed.com/products/1297538-32-9.html
BioCrick	BCC3796	http://www.biocrick.com/ODM-201-BCC3796.html
BioSynth	J-690121	https://www.biosynth.com/en/products/all-products/products/J-690139.html
Chem Scene	CS-5174	http://www.chemscene.com/1297538-32-9.html
Chemspace	CSSB00102419696	https://chem-space.com/CSSB00102419696
CSNpharm	CSN17664	https://www.csnpharm.com/products/odm-201.html
DC Chemicals	DC8700	http://www.dcchemicals.com/product_show-ODM_201.html
eNovation Chemicals	D516673	http://www.enovationchem.com/productDetails.asp?productID=D516673
eNovation Chemicals	D549353	https://www.enovationchem.com/ProductDetails.asp?ProductID=D549353
eNovation Chemicals	Y0974423	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974423
Excenen	EX-A759	http://www.excenen.com/searchresultlist.php?id=1297538-32-9
iChemical	EBD3331867	http://www.ichemical.com/products/1297538-32-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01343800	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343800
MedChem Express	HY-16985	https://www.medchemexpress.com/ODM-201.html
Smolecule	S537977	http://www.smolecule.com/products/s537977
Synblock Inc	SB18882	http://www.synblock.com/product/1297538-32-9.html
THE BioTek	bt-277298	https://www.thebiotek.com/product/inhibitors/bt-277298

PubMed

Title	Date	PubMed
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.	2015	26313416
ODM-201 tablets complete phase I.	2015 Dec	26526759

Patents

Sample Use Guides

In Vivo Use Guide

In the Phase II patients were treated orally with 200 mg/day, 400 mg/day or 1400 mg/day of ODM-201.

Route of Administration: Oral

In Vitro Use Guide

Antagonism to wtAR was determined using AR-HEK293 cells treated with ODM-201 up to 1 uM. The cells were treated with test compounds and 0.45 nM testosterone in steroid-free assay medium. After 24 hours cells were lysed and luciferase activity was measured.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:42:41 GMT 2025` Edited by `admin` on `Mon Mar 31 23:42:41 GMT 2025`
Record UNII	X05U0N2RCO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DAROLUTAMIDE

Official Name

English

darolutamide [INN]

Preferred Name

English

NUBEQA

Brand Name

English

1H-PYRAZOLE-3-CARBOXAMIDE, N-((1S)-2-(3-(3-CHLORO-4-CYANOPHENYL)-1H-PYRAZOL-1-YL)-1-METHYLETHYL)-5-(1-HYDROXYETHYL)-

Systematic Name

English

DAROLUTAMIDE [JAN]

Common Name

English

N-((2S)-1-(3-(3-CHLORO-4-CYANOPHENYL)-1H-PYRAZOL- 1-YL)PROPAN-2-YL)-5-((1RS)-1-HYDROXYETHYL)-1H-PYRAZOLE- 3-CARBOXAMIDE

Systematic Name

English

ODM-201

Code

English

DAROLUTAMIDE [MI]

Common Name

English

DAROLUTAMIDE [ORANGE BOOK]

Common Name

English

BAY1841788

Code

English

Darolutamide [WHO-DD]

Common Name

English

DAROLUTAMIDE [USAN]

Common Name

English

BAY-1841788

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C146993